Company intelligence / Profile preview

FELIQS

Kurume, Fukuoka, Japan

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Lead candidate FLQ-101 for prevention of retinopathy of prematurity (ROP) is ready for Phase 1b/2a in the US with orphan drug and fast track designation from the FDA. FLQ-104 for AMD is entering Phase I. Proof of concept has been achieved in animal studies, with demonstrated efficacy in previous prospective human clinical trials of this approach. Commercial launch for FLQ-101 is projected for 2027.[2][4][5]

Therapeutic areas: DermatologyOphthalmology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

4 assets

FLQ-104

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Major American pharmaceutical company (undisclosed, Series A lead)Beyond Next VenturesJapan Science and Technology AgencyMitsubishi UFJ Capital Co., Ltd.Keio Innovation Initiative, Inc.FFG Venture Business Partners Co., Ltd.

Beyond the preview

Go deeper on FELIQS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FELIQS.

Explore the full profile